Movatterモバイル変換


[0]ホーム

URL:


CN119144151A - Preparation of hydrogels and uses thereof - Google Patents

Preparation of hydrogels and uses thereof
Download PDF

Info

Publication number
CN119144151A
CN119144151ACN202310704935.7ACN202310704935ACN119144151ACN 119144151 ACN119144151 ACN 119144151ACN 202310704935 ACN202310704935 ACN 202310704935ACN 119144151 ACN119144151 ACN 119144151A
Authority
CN
China
Prior art keywords
intermediate product
preparation
action
hydrogel
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310704935.7A
Other languages
Chinese (zh)
Inventor
陈国颂
高晨迪
张恩菘
徐襄云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Hong Kong Macao Dawan District Institute Of Precision Medicine Guangzhou
Fudan University
Original Assignee
Guangdong Hong Kong Macao Dawan District Institute Of Precision Medicine Guangzhou
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Hong Kong Macao Dawan District Institute Of Precision Medicine Guangzhou, Fudan UniversityfiledCriticalGuangdong Hong Kong Macao Dawan District Institute Of Precision Medicine Guangzhou
Priority to CN202310704935.7ApriorityCriticalpatent/CN119144151A/en
Priority to PCT/CN2024/099071prioritypatent/WO2024255806A1/en
Publication of CN119144151ApublicationCriticalpatent/CN119144151A/en
Pendinglegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The invention belongs to the field of biological materials and biomedicine, and particularly relates to preparation and application of hydrogel, wherein the hydrogel is composed of A, B polymers, wherein main chains of A, B polymers are composed of lysine and glutamic acid which form an amide bond through polycondensation, alkynyl groups on main chains of A and B polymers can be connected with functional molecules, the functional molecules are selected from one or more of peptide fragments, fluorophores, antibacterial molecules, growth factors, functional oligosaccharides or polysaccharides, the amino terminal end of the polymer A can be respectively connected with different types of monosaccharides or oligosaccharides, the amino terminal end of the polymer B is connected with any phenylboronic acid structure, and the phenylboronic acid structure comprises one or more of phenylboronic acid half esters and carbonyl phenylboronic acid half esters.

Description

Preparation of hydrogels and uses thereof
Technical Field
The invention belongs to the field of biological materials and biomedicine, and particularly relates to preparation and application of hydrogel.
Background
Hydrogels are a class of three-dimensional networks composed of hydrophilic polymer chains that crosslink to form a matrix (Annabi N.,Tamayol A.,Uquillas J.A.,et al.25th Anniversary Article:Rational Design and Applications of Hydrogels in Regenerative Medicine[J].Advanced Materials,2014,26(1):85-124.). with a high water content, which, due to the hydrophilic portion of the polymer backbone in the hydrogel, can retain a large amount of water within the hydrogel material, thus having similar physicochemical properties as liquid water, while hydrogels that exhibit macroscopic solid state rheological behavior (Guan Q.-F.,Yang H.-B.,Han Z.-M.,et al.Sustainable Cellulose-Nanofiber-Based Hydrogels[J].ACS Nano,2021,15(5):7889-7898&Davidson M.D.,Ban E.,Schoonen A.C.M.,et al.Mechanochemical Adhesion and Plasticity in Multifiber Hydrogel Networks[J].Advanced Materials,2020,32(8):1905719.). have become advanced materials for new applications ranging from drug delivery to wound dressing healing, vision enhancing contact lenses, food, tissue engineering, and many other technical applications. Many parts of the human body contain hydrogels in the form of extracellular matrix, collagen, mucus, gelatin, cartilage, meniscus, epidermis, vitreous humor and tendons. The hydrophilicity and 3D structure of hydrogels provide them with the ability to hold large amounts of water or biological fluids. Hydrogels consist of dynamically crosslinked structures, which enable them to maintain the integrity of the hydrogel network. This property of hydrogels makes them capable of mimicking many of the properties (Brown T.E.,Anseth K.S.Spatiotemporal hydrogel biomaterials for regenerative medicine[J].Chemical Society Reviews,2017,46(21):6532-6552&Thiele J.,Ma Y.,Bruekers S.M.C.,et al.25th Anniversary Article:Designer Hydrogels for Cell Cultures:A Materials Selection Guide[J].Advanced Materials,2014,26(1):125-148.), of the extracellular matrix in tissues, for a number of applications in tissue engineering and biomedical applications.
Macroscopic hydrogel materials formed from sugar-based macromolecules can be used in tissue engineering applications. The natural extracellular matrix (ECM) consists of a complex network of biological macromolecules surrounding the cells, which on the one hand provides different mechanical properties in different tissues, which are important for stabilizing tissue structure and mechanics, and on the other hand has a complex macromolecular composition which provides many bioactive signals to the cells surrounded by it. The ECM's properties in both mechanical and biochemical signals play an important role in modulating various cellular behaviors- (Frantz C.,Stewart K.M.,Weaver V.M.The extracellular matrix at a glance[J].Journal of Cell Science,2010,123(24):4195-4200.). sugar-based macromolecular materials are of particular advantage as scaffolds for tissue engineering, they can provide not only adjustable mechanical properties by virtue of rich chemical structures and supramolecular interactions, but also biochemical signals mediating cell-scaffold interactions as bioactive molecules, so that sugar-based macromolecular materials can serve as ideal ECM mimics to construct scaffolds for biological materials to modulate related cellular behaviors and promote tissue regeneration (O'Brien F.J.Biomaterials&scaffolds for tissue engineering[J].Materials Today,2011,14(3):88-95&Place E.S.,Evans N.D.,Stevens M.M.Complexity in biomaterials for tissue engineering[J].Nature Materials,2009,8(6):457-470.).
Conventional hydrogels, which use synthetic polymers such as polyethylene glycol, polyvinyl alcohol, poly (2-hydroxyethyl methacrylate), polyacrylamide, etc., as raw materials and are crosslinked by chemical reaction, generally exhibit high mechanical properties and have a certain degradation ability. However, conventional hydrogels generally lack bioactivity and limited biocompatibility, covalent crosslinking is such that they do not have dynamic self-adaptability to cells, and generally have low adhesion strength to moist surfaces and biological tissues (Zhao Y.,Song S.,Ren X.,et al.Supramolecular Adhesive Hydrogels for Tissue Engineering Applications[J].Chemical Reviews,2022,122(6):5604-5640.).. Various hydrogels based on alginate, collagen, agarose, hyaluronic acid and chitosan can be prepared by a physical crosslinking method using natural biomacromolecules, which have better biocompatibility and have a certain bioactivity, but the lack of sufficient mechanical properties of these materials greatly limits the application range thereof (LiY.,Rodrigues J.,Tomás H.Injectable and biodegradable hydrogels:gelation,biodegradation and biomedical applications[J].Chemical Society Reviews,2012,41(6):2193-2221.).
Mooney et al developed a dual network polymer hydrogel that simultaneously formed an ionic interaction cross-linked and covalent cross-linked network, the strength of which was significantly improved, was able to withstand deformation by 20 times its initial length, and the energy to break was greatly improved. However, the existence of polyacrylamide and covalent crosslinking in the gel network still reduces (Sun J.-Y.,Zhao X.,Illeperuma W.R.K.,et al.Highly stretchable and tough hydrogels[J].Nature,2012,489(7414):133-136.). the degradation performance and dynamic stress relaxation performance of the gel network, the range of the modulus of the existing supermolecule hydrogel is generally narrow, the strength difference of different tissues is large, and the modulus range of the supermolecule hydrogel can not meet the strength requirement of tissue repair.
With the continuous development of science, technology and medical level and the continuous improvement of the requirements of people on the quality and efficiency of medical treatment, the types of medical adhesives are more and more, wherein the medical adhesives can be mainly divided into two main types, namely soft tissue adhesives and hard tissue adhesives, wherein the soft tissue adhesives can be used for bonding the parts of skin, organs, nerves, blood vessels, mucous membranes and the like, the medical alpha-cyanoacrylate-based adhesive and the fibrin biological-based adhesive are adopted, the fibrin biological-based adhesive is generated in blood, and the possibility of mutual infection of infectious diseases such as hepatitis, AIDS and the like exists in the use process, and although the autologous blood can be adopted, the medical adhesives are not applicable to emergency treatment, and the strength and the speed of the medical adhesives are not ideal. Among them, eye surgery is a fundamental clinical means for solving various eye diseases, and suture suturing is a standard method for repairing eye incisions at present, but it is easy to cause postoperative complications such as irritation, inflammation, etc. In order to overcome the defects of the traditional suturing, the medical gel-type adhesive is gradually developed in recent years, and the common adhesive comprises(Baxter AG)、However, the composition has the limitations of poor biocompatibility, weak adhesive strength, low-temperature preservation and the like, and cannot meet the requirements of clinical practical application.
Disclosure of Invention
In a first aspect, the invention provides a hydrogel, which consists of A, B polymers, wherein the main chains of A, B polymers are formed by forming an amide bond through polycondensation of lysine and glutamic acid, the value of n is 8-100, A, B polymers are polymers with arbitrary branching algebra respectively, and the structural formulas of A, B polymers are shown as a and b:
ra on the main chains of the A, B polymers is selected from (c) or (d), and the structural formulas are shown as (c) and (d):
Or alternatively
Wherein Ra1 is A, B, rb is A, B, rc is monosaccharide or oligosaccharide connected with Rb end of polymer A, rd is any phenylboronic acid structure connected with Rb end of polymer B.
Further, the functional molecule is selected from one or more of peptide fragments, fluorophores, antibacterial molecules, growth factors, functional oligosaccharides or polysaccharides.
Further, the peptide fragment is selected from cell-adhesive peptides, antibacterial peptides, hormone peptides, immunomodulatory peptides, and antioxidant peptides, and the functional oligosaccharide or polysaccharide may be one or more of glycosaminoglycan, fucan, alginate, hyaluronic acid, and chitosan.
Further, the Rb branched structure is a branching reaction that can be performed by A, B two polymers at the amino terminal of their side chains.
Further, the branching algebra is preferably 0 to 5 generations.
Further, the branching of the amino terminal is performed by branching with a compound containing an amino group to achieve a function of increasing the number of amino terminals.
Further, the branching method is selected from branching of compounds containing at least two amino groups and one carboxyl group or branching methods with polyamide-amine forming materials;
Further, the compound may be selected from one or more of lysine, diaminopropionic acid, diaminobutyric acid, diaminocaproic acid, diaminoheptanoic acid.
Further, the amino terminal of the branched structure of the polymer a may be linked to different kinds of mono-or oligosaccharides, respectively.
Further, the monosaccharide may be selected from one or more of mannose, glucose, galactose, fructose, xylose, fucose, gulose, idose, lyxose, mannuronic acid, glucuronic acid, galacturonic acid, guluronic acid, and the like, and derivatives thereof.
Further, the oligosaccharide may be one or more of any oligosaccharide.
Further, the amino terminal of the branched structure of the polymer B is connected with any phenylboronic acid structure, including one or more of phenylboronic acid half ester and carbonyl phenylboronic acid half ester.
Further, A, B polymers in the hydrogels are mixed in a 10% -20% solids solution.
Further, the proportion of A, B polymers in the hydrogel is 1-2:2-1.
Further, the strength of the hydrogel is 10Pa-100000Pa.
Further, the hydrogel has superior tissue adhesion, shear resistance, visible light transmittance, and/or biodegradability.
In a second aspect, the present invention provides the use of a hydrogel according to the first aspect for the preparation of a skin wound material.
Further, the skin wound refers to a wound of skin or mucous membrane caused by burn, mechanical injury or inflammation, and the mucous membrane comprises oral mucosa or nasal mucosa and the like.
Further, the trauma repair substance may be a drug or medical device.
In a third aspect, the present invention provides the use of a hydrogel according to the first aspect for the preparation of a suturing agent for conjunctival or corneal transplants.
Further, the use may be to improve the adhesion of conjunctival or corneal transplants in situ and closure of wounds.
Further, the application can also be used as a suture agent to replace a suture.
In a fourth aspect, the present invention provides a medical formulation comprising a hydrogel according to the first aspect of the invention.
Further, the preparation also contains preparations for diminishing inflammation, stopping bleeding and the like, pharmaceutical excipients and the like.
In a fifth aspect, the present invention provides a use of the hydrogel of the first aspect for preparing a bone repair material.
Further, the bone repair includes, but is not limited to, trauma, spinal, joint, orthopedic, and the like.
In a sixth aspect, the present invention provides a method for preparing the hydrogel according to the first aspect:
s1, preparing an intermediate product 1:
The starting materials Boc-Lys (Boc) -OH, H-Glc (OMe) -OMe.HCl undergo a condensation reaction under the action of reagent EDC, HOBT, DIPEA to give intermediate 1.
S2, preparing an intermediate product 2:
The intermediate product 1 undergoes deprotection reaction under the action of a reagent ethyl hydrogen chloride acetate solution to obtain an intermediate product 2.
S3, preparing an intermediate product 3:
The intermediate product 2 and raw material Boc-Lys (Boc) -OH undergo condensation reaction under the action of a reagent EDC, HOBT, DIPEA to obtain an intermediate product 3.
S4, preparation of intermediate products 4 and 5:
the intermediate product 1 or 3 is subjected to deprotection reaction under the action of lithium hydroxide reagent to obtain intermediate products 4 or 5 respectively.
S5, preparation of intermediate products 6, 7 and 8:
The raw material Boc-Glc-OH or the intermediate product 4 or 5 and the raw material pentafluorophenol are subjected to condensation reaction under the action of a reagent EDC to obtain intermediate products 6, 7 and 8 respectively.
S6, preparation of an intermediate product 9:
The raw material Boc-Lys (Boc) -OH and propargylamine are subjected to condensation reaction under the action of a reagent EDC, HOBT, DIPEA to obtain an intermediate product 9.
S7, preparation of intermediate 10 (Mb):
intermediate 9 undergoes deprotection under the action of ethyl hydrogen chloride solution to give intermediate 10 (Mb).
S8, preparation of intermediate 11 (Mc):
The raw materials Boc-aminoxyacetic acid and pentafluorophenol undergo condensation reaction under the action of a reagent EDC to obtain an intermediate product 11 (Mc).
S9, preparation of intermediate products 12, 13 and 14:
Intermediate 6 or 7 or 8 and intermediate 10 (Mb) are polymerized under the action of DIPEA reagent to give intermediates 12, 13, 14.
S10, preparation of intermediate products 15, 16 and 17:
intermediate 12 or 13 or 14 undergoes deprotection reaction under the action of trifluoroacetic acid reagent to give intermediates 15, 16, 17, respectively.
Preparation of the B component (products 18, 19, 20):
Intermediate 15, 16 or 17 and raw material Bob react under the action of sodium borohydride reagent to obtain product B components (products 18, 19 and 20) respectively.
S12, preparation of intermediate products 21, 22 and 23:
intermediate 15 or 16 or 17 and intermediate 11 (Mc) undergo a condensation reaction under the action of DIPEA reagent and further undergo a deprotection reaction under the action of trifluoroacetic acid reagent to give intermediates 21, 22, 23, respectively.
Preparation of component a (products 24, 25, 26):
the intermediate product 21 or 22 or 23 and the raw material monosaccharide or oligosaccharide undergo condensation reaction under the action of reagent aniline to respectively obtain a product A component (products 24, 25 and 26);
S14, synthesis of hydrogel
The solid content of the component A or the component B is 12-20wt%.
Drawings
FIG. 1 molecular Structure of raw materials A and B
FIG. 2A/B component branching Structure Change
FIG. 3 synthetic routes for intermediates M0-a, M1-a, M2-a, mb, mc
FIG. 41 HNMR result of 1
FIG. 51 HNMR result of2
FIG. 61H NMR result of 3
FIG. 71 HNMR result of4
FIG. 81 HNMR result of5
FIG. 91 HNMR result of6
FIG. 101 HNMR result of7
FIG. 111 HNMR result of8
FIG. 121 HNMR result of9
FIG. 131 HNMR result of 10
FIG. 141 HNMR result of 11
FIG. 15 Synthesis routes of P0, P1, P2, A component (P0-Man (Glc), P1-Man (Glc), P2-Man (Glc)), B component (P0-Bob, P1-Bob, P2-Bob)
FIG. 161 HNMR result of 12
FIG. 171 HNMR result of 15
Fig. 181 HNMR result ofcompound and 16
FIG. 191 HNMR result ofcompound and 17
FIG. 201 HNMR result of 18
FIG. 211 HNMR result of 19
FIG. 221 HNMR result of20
FIG. 231 HNMR result of21
FIG. 241 HNMR result of22
FIG. 251 HNMR result of23
FIG. 261 HNMR result of24 (P0-Man)
FIG. 271 HNMR result of25 (P1-Man)
FIG. 281 HNMR result of25 (P1-Glc)
FIG. 291 HNMR result of26 (P2-Man)
FIG. 30 Synthesis routes of polymers P0-Bob-1, P1-Bob-1, P2-Bob-1 with a modified phenylboronate structure
FIG. 311 HNMR result ofP1-Bob-1
FIG. 321 H NMR result of30 (P2-Man-RGD)
FIG. 33 Synthesis routes of polymers G0, G1, G2 with varying branching patterns
FIG. 341 HNMR result ofG0.5
FIG. 351 HNMR result ofG1.0
FIG. 361 HNMR result ofG1.5
FIG. 371 HNMR result of G2.0
FIG. 38 tissue adhesion Strength ((a)P0-Man+P0-Bob,P1-Man+P1-Bob,P2-Man+P2-Bob;(b)P2-Man+P0-Bob,P2-Man+P0-Bob,P2-Man+P2-Bob;(c)P1-Bob+P1-Glc,P1-Bob+P1-Man) FIG. 39 shear resistance test
FIG. 40 construction of mechanical Strength of hyperbranched polypeptide hydrogels (a) P0-Man+P0-Bob (b) P1-Man+P1-Bob (c) P2-Man+P2-Bob) under the same branching System conditions with a solids content of 12wt%
FIG. 41 construction of mechanical Strength of hyperbranched polypeptide hydrogels (a) P2-Man+P2-Bob (b) P2-Man+P1-Bob (c) P0-Man+P0-Bob (d) P1-Man+P0-Bob (e) P2-Man+P0-Bob under different branching System conditions with a solids content of 12wt%
FIG. 42 mechanical strength of gel formed by P1-Glc+P1-Bob and P1-Man+P1-Bob at neutral
FIG. 43 test of adhesion stability of hydrogels to in vitro pigskin under external force
FIG. 44 test gel adhesion stability test under water
FIG. 45 light transmittance test
FIG. 46 in vitro degradation experiment
FIG. 47 gel autologous conjunctival graft test
Figure 48 biomechanical test of hydrogel closure in vitro porcine eyeball cornea incision
FIG. 49 biosafety test
FIG. 50 cell safety test
FIG. 51 rabbit autologous conjunctival transplantation assay
FIG. 52 effect of cornea damage repair in animal model of cornea damage repair
FIG. 53 bone defect repair Effect in bone defect repair animal model
Detailed Description
EXAMPLE 1 Synthesis of hydrogel Pre-materials
In this example, the starting materials required for hydrogel synthesis include Boc-L-glutamic acid (Boc-Glc-OH), (S) -2, 6-di-tert-butoxycarbonylaminohexanoic acid (Boc-Lys (Boc) -OH), L-glutamic acid dimethyl ester hydrochloride (H-Glc (OMe) -OMe. HCl), pentafluorophenol, mannose (or different types of mono-or oligosaccharides), phenylboronic acid half ester (Bob), boc-aminooxyacetic acid, propargylamine, all commercially available.
The required reagents include 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 1-Hydroxybenzotriazole (HOBT), N-Diisopropylethylamine (DIPEA), lithium hydroxide, ethyl hydrogen chloride acetate solution, sodium borohydride, trifluoroacetic acid, anhydrous diethyl ether, and aniline, all of which are commercially available.
1.1 Molecular Structure
1.1.1 Raw material molecular basic Structure
The structure diagram of the raw material A component and the raw material B component is shown in figure 1.
1.2 Molecular expansion Structure
The change in branching structure of 1.2.1A/B components is shown in FIG. 2.
1.2.2A component sugar changes
R=mannose (Man) Or r=glucose (Glc)
1.3 Preparation and characterization of Components A and B
1.3.1 Preparation of intermediates M0-a, M1-a, M2-a, mb, mc (see FIG. 3);
1. synthesis of Compound 1
(1) Boc-Lys (Boc) -OH, EDC, HOBT and H-Glc (OMe) -OMe.HCl were dissolved in dry dichloromethane.
(2) DIPEA or triethylamine is slowly added dropwise under ice water bath condition. The ratio of the amounts of starting materials was Boc-Lys (Boc) -OH: EDC: HOBT: H-Glc (OMe) -OMe.HCl: DIPEA or triethylamine=1:1:1:1:1.
(3) And removing the ice water bath, continuously stirring for 6-36 h, and washing with dilute hydrochloric acid, dilute sodium hydroxide and saturated saline water after the reaction is finished. After the organic phase was separated, the crude product was purified by silica gel column chromatography to give a white solid (see fig. 4).
2. Synthesis of Compound 2
(1) An excess of saturated ethyl hydrogen chloride acetate solution was slowly added dropwise to compound 1 under ice water bath conditions.
(2) The ice-water bath was removed and the reaction was stirred for 30min. During the reaction, a large amount of white precipitate was generated.
(3) After the reaction, a white solid was obtained by suction filtration, washed with ethyl acetate several times and dried under vacuum at room temperature (see fig. 5).
3. Synthesis of Compound 3
(1) Boc-Lys (Boc) -OH, EDC, HOBT and Compound 2 were dissolved in dry dichloromethane.
(2) Under the ice water bath condition, DIPEA or triethylamine is slowly added dropwise, and the ratio of the raw materials is that the compound 2:Boc-Lys (Boc) -OH is EDC:HOBT is DIPEA or triethylamine=1:2:2:2:2. The ice water bath was removed and the reaction was continued with stirring for 24h.
(3) After the completion of the reaction, the reaction mixture was washed with diluted hydrochloric acid, diluted sodium hydroxide and saturated brine, respectively. The organic phase was separated, dried over anhydrous magnesium sulfate, filtered and dried by spin. The crude product was purified by column chromatography on silica gel to finally obtain a white solid (see fig. 6).
4. Synthesis of Compound 5
(1) Compound 1 or 3 was dissolved in a mixed solvent of methanol/water=4:1.
(2) Under the ice water bath condition, slowly adding lithium hydroxide or sodium hydroxide or potassium hydroxide, wherein the mass ratio of the raw materials is that the compound 1 or3 is lithium hydroxide or sodium hydroxide or potassium hydroxide=1:2.
(3) The ice-water bath was removed and the reaction continued for 12h. Then, dilute hydrochloric acid was added to the reaction solution to adjust the pH to 5.
(4) After removing methanol from the system under reduced pressure, the product was extracted 3 times with ethyl acetate, and the organic phases were combined and dried by spin to finally obtain a white product (see fig. 7, 8).
5. Synthesis of Compounds 6 to 8 (Ma)
(1) Compound 4 or 5 or Boc-Glc-OH and EDC, respectively, were dissolved in dry dichloromethane and pentafluorophenol was slowly added under ice water bath.
(2) The ratio of the amounts of starting materials was compound 4 or 5 or Boc-Glc-OH: EDC: pentafluorophenol=1:2:2. After removing the ice water bath, stirring and reacting for 12h at normal temperature.
(3) After the reaction was completed, the excess solvent was distilled off under reduced pressure, and the crude product was separated by silica gel column chromatography to obtain a white solid (see FIGS. 9,10, 11).
6. Synthesis of Compound 9
(1) Boc-Lys (Boc) -OH, EDC, HOBT and propargylamine were dissolved in dry dichloromethane. DIPEA or triethylamine was slowly added dropwise under ice water bath.
(2) The ratio of the amounts of starting materials was Boc-Lys (Boc) -OH: EDC: HOBT: propargylamine: DIPEA or triethylamine=1:1:1:1:1. After removing the ice water bath, the reaction was continued for 24 hours.
(3) After the reaction, the system was washed with dilute hydrochloric acid and dilute sodium hydroxide solution, respectively, to separate out an organic phase. The crude product was purified by silica gel column chromatography to give the product ((see FIG. 12)).
7. Synthesis of Compound 10 (Mb)
(1) And cooling the compound 9 by using an ice water bath, slowly dropwise adding and dissolving excessive hydrogen chloride saturated ethyl acetate solution, removing the ice water bath, and continuing to react for 0.5-6 h.
(2) After the reaction, a white solid was obtained by suction filtration, washed with ethyl acetate several times and dried in vacuo to obtain the product (see fig. 13).
8. Synthesis of compound 11 (Mc):
(1) Boc-aminooxyacetic acid, EDC was dissolved in dry dichloromethane. Under ice water bath, pentafluorophenol was slowly added. The ratio of the amounts of the starting materials was Boc-aminoxyacetic acid to EDC to pentafluorophenol=1:1:1.
(2) After removing the ice water bath, stirring was continued for reaction for 24 hours. After the reaction was completed, the precipitate was filtered off, washed several times with methylene chloride, and dried in vacuo to give a white product (see fig. 14).
1.4P0, P1, P2, preparation of A component (A component comprising sugar molecule changed to glucose) (P0-Man (Glc), P1-Man (Glc), P2-Man (Glc)), B component (P0-Bob, P1-Bob, P2-Bob) (synthetic route see FIG. 15)
1.4.1 Synthesis of Compounds 12, 13, 14 (P0, P1, P2)
(1) Compound 6 or 7 or 8 and compound 10 were slowly dissolved in anhydrous DMSO or DMF. DIPEA or triethylamine was slowly added dropwise under ice water bath.
(2) The ratio of the amounts of the starting materials is compound 6 or 7 or 8, compound 10:dipea or triethylamine=1:1:2. After removing the ice water bath, stirring was continued for 48 hours.
(3) After the reaction, methanol or ethanol was added under ice water bath to dilute the solution, and then the product was precipitated in diethyl ether and centrifugally filtered. This procedure was repeated 3 times, and finally the precipitate was filtered off and dried in vacuo to give the product (see fig. 16).
1.4.2 Synthesis of Compounds 15, 16, 17
(1) Compound 12 or 13 or 14 was dissolved in excess trifluoroacetic acid under ice water bath conditions and stirring was continued for 4.5h after removal of the ice water bath.
(2) After the reaction, the solution was diluted with methanol, the product was precipitated in diethyl ether, and the product was filtered off, washed several times with diethyl ether and dried under vacuum to give a white product (see FIGS. 17,18, 19).
1.4.3 Synthesis of Compounds 19, 20 (P0-Bob, P1-Bob, P2-Bob)
(1) The flask was charged with compound 15 or 16 or 17, phenylboronic acid half ester and sodium borohydride and a vacuum was pulled.
(2) The ratio of the raw materials is that the compound 15 or 16 or 17 is phenylboronic acid half ester and sodium borohydride=1:1:4.
(3) Then slowly dropwise adding methanol under the ice water bath condition. The ice-water bath was then removed and the reaction stirred for an additional 24h.
(4) After the reaction, the mixture was dialyzed against deionized water using a dialysis bag having a molecular weight cut-off of less than 2000, and lyophilized to give a white solid (see FIGS. 20,21, 22).
1.4.4 Synthesis of Compounds 21, 22, 23
(1) Compound 15 or 16 or 17 and compound 11 (Mc) were dissolved in anhydrous DMSO or DMF.
(2) Under the ice water bath condition, DIPEA or triethylamine is slowly added dropwise. The ratio of the amounts of starting materials is compound 15 or 16 or 17: compound 11: dipea or triethylamine=1:1:2.
(3) After removing the ice water bath, stirring reaction is continued for 24 hours.
(4) After the reaction was completed, the solution was diluted with methanol under ice-water bath conditions, and the product was precipitated with diethyl ether. This procedure was repeated 3 times, and finally the precipitate was filtered off and the white solid was dried under vacuum at room temperature.
(5) The solid was then dissolved in excess trifluoroacetic acid under ice water bath conditions. The ice water bath was removed and stirring was continued for 4.5h.
(6) After the reaction, the reaction mixture was diluted with methanol in ice-water bath and the product was isolated by precipitation with diethyl ether. After filtration, the mixture was washed with diethyl ether several times and dried under vacuum at room temperature to give a white solid (see FIGS. 23,24, 25).
1.4.5 Synthesis of Compounds 24, 25, 26 (P0-Man (Glc), P1-Man (Glc), P2-Man (Glc) (synthetic route see FIG. 30)
(1) In an acetic acid/sodium acetate buffer solution with ph=4.2, compound 21 or 22 or 23, mannose (glucose) and aniline 10 to 100 μl are dissolved therein, and stirred for 6 to 24 hours at 37 ℃.
(2) The ratio of the amounts of the raw materials is that of the compound 21 or 22 or 23, mannose (glucose) =1:1.
(3) Dialyzing with dialysis bag with molecular weight cut-off less than 2000, and lyophilizing to obtain white solid (26, 27,28,29, 30). 1.4.6 Synthesis of Compound 27 (P0-Bob-1)
(1) Compound 15 (0.155 g,0.53 mmol) and Bob-1 (0.199g, 0.58 mmol) were dissolved in 1.5mL anhydrous DMF, cooled in an ice-water bath, and DIPEA (0.3 mL,1.63 mmol) was slowly added dropwise to the system, and the ice-water bath was removed and stirred for 6h. After the reaction was completed, the reaction system was diluted with 5mL of methanol and then precipitated with 250mL of diethyl ether. This step was repeated 3 times to substantially remove DIPEA. Finally, the product was dried in vacuo to give a white solid (0.197g, 82%).
1.4.7 Synthesis of Compound 28 (P1-Bob-1)
(1) Compound 16 (0.165 g,0.39 mmol) and Bob-1 (0, 295g,0.86 mmol) were dissolved in 1.5mL anhydrous DMSO, cooled in an ice-water bath, and DIPEA (0.3 mL,1.63 mmol) was slowly added dropwise to the system, and the ice-water bath was removed and stirred for 6h.
(2) After the reaction was completed, the reaction system was diluted with 5mL of methanol and then precipitated with 250mL of diethyl ether. This step is repeated 2 to 3 times to sufficiently remove the DIPEA.
(3) Finally, the product was dried in vacuo to give a white solid (0.219 g, 76%).
Synthesis of 1.4.8 Compound 29 (P2-Bob-1)
(1) Compound 17 (0.130 g,0.19 mmol) and Bob-1 (0.294 g,0.86 mmol) were dissolved in 1.5mL anhydrous DMF, cooled in an ice-water bath, and DIPEA (0.3 mL,1.63 mmol) was slowly added dropwise to the system, and the ice-water bath was removed and stirred for 6h.
(2) After the reaction was completed, the reaction system was diluted with 5mL of methanol and then precipitated with 250mL of diethyl ether. This step was repeated 3 times to substantially remove DIPEA. The product was finally dried in vacuo to give a white solid (0.182 g, 72%) (see fig. 31).
Synthesis of 1.4.9 Compound 30 (P2-Man-RGD)
(1) The flask was charged with compound 26, N3-GRGDSP peptide, DMF, cuprous bromide, PMDETA and deoxygenated.
(2) Heating to 50 ℃ and stirring to react for 24 hours.
(3) After the reaction is finished, dialyzing in deionized water by using a dialysis bag with the molecular weight cut-off of less than 2000, and freeze-drying to obtain white solid.
The white solid product P2-Man-RGD (FIG. 32).
1.5 Preparation and characterization of G0, G1, G2 with varying branching patterns (see FIG. 33)
1.5.1G1.0 Synthesis
(1) The polymer backbone G0 and monomer methyl acrylate MA are respectively dissolved in anhydrous methanol at room temperature, and then the methanol solution of G0 is slowly dripped into the methanol solution of MA, wherein the mass ratio of raw materials is G0 (n-NH 2): MA=1:30.
(2) Room temperature after the dripping is completed the reaction was stirred for 48h. After the reaction, the unreacted MA and the solvent methanol are dried by spin to obtain a product G0.5.
(3) Subsequently, G0.5 and ethylenediamine as reaction raw materials were dissolved in anhydrous methanol at room temperature, respectively, and then a methanol solution of G0.5 was slowly dropped into a methanol solution of ethylenediamine, the ratio of the amounts of the raw materials being G0.5 (n-COOR): ethylenediamine=1:50.
(4) Room temperature after the dripping is completed the reaction was stirred for 48h. After the reaction, unreacted ethylenediamine and methanol solvent were spin-dried to obtain a product G1.0 (see fig. 34, 35).
1.5.2G2.0 Synthesis
(1) The polymer G1.0 and the monomer methyl acrylate MA were dissolved in absolute methanol at room temperature, respectively, and then the methanol solution of G0 was slowly dropped into the methanol solution of MA, the ratio of the amounts of the raw materials being G1.0 (n-NH 2): ma=1:50. Room temperature after the dripping is completed the reaction was stirred for 48h.
(2) After the reaction was completed, unreacted MA and methanol solvent were spin-dried to obtain a product G1.5 (see fig. 36). Subsequently, G1.5 and ethylenediamine as reaction raw materials were dissolved in anhydrous methanol at room temperature, respectively, and then a methanol solution of G1.5 was slowly dropped into a methanol solution of ethylenediamine, the ratio of the amounts of the raw materials being G1.5 (n-COOR): ethylenediamine=1:50.
(3) Room temperature after the dripping is completed the reaction was stirred for 48h. After the reaction was completed, unreacted ethylenediamine and methanol solvent were spin-dried to obtain a product G2.0 (see fig. 37).
Example 2 hydrogel preparation and Properties
2.1 Gel preparation method
Firstly, preparing polymer solution of component A (Pn-Man, pn-Glc (n=0, 1, 2)), and component B (polymer solution of Pn-Bob (n=0, 1, 2): A, B, controlling the solid content to be 12-20wt%, respectively dissolving hyperbranched glycopeptide polymers (P0-Man, P1-Man and P2-Man) in pure water to obtain component A solution, respectively dissolving hyperbranched phenylboronic acid half-ester polypeptides (P0-Bob, P1-Bob and P2-Bob) in pure water, and regulating the pH to 8 to obtain component B solution, regulating the ratio of a donor/acceptor (sugar unit/phenylboronic acid unit) in component A, B solution to be 2:1, uniformly mixing the two solutions after the components are completely dissolved in a solvent, and standing to obtain a series of hyperbranched polypeptide hydrogel materials.
2.2 Performance test of gels
2.1.1 Hydrogel adhesion stability test
Pig skin was trimmed to 1cm x 1cm size, fixed with quick-drying adhesive to 1cm x 4cm size acrylic plates, and a total volume of 20 μl of hydrogel was applied between the two pig skins. After waiting 10 minutes for the gel to fully cure, the two ends of the spline were secured with clamps, the sample was pulled at a speed of 2mm/min using a ZP50 pulling machine until fully separated, and the maximum tissue adhesion strength reached before fully separating the sample was recorded.
The experimental results of the binding capacities of the two components show that the increase of the branching degree can effectively increase the number of the terminal functionalized sites, further increase the number of the binding sites, and finally further increase the molar binding enthalpy of the two components, namely better gel stability (see fig. 38a and 38 a), and the binding exotherms of P1-Glc+P1-Bob and P1-Man+P1-Bob are almost the same, so that the binding capacities are very close (see fig. 38 c).
2.1.2 Shear test
The gel provides effective adhesion in the 1:2 and 2:1 ratio ranges, has good tissue adhesion and shearing resistance, and is suitable for application in skin wound repair and conjunctival transplantation (see figure 39).
As can be seen from the rotameter test, the gel strength of A, B can be precisely controlled within the range of 10Pa to 100000Pa (see figures 40 and 41), and as can be seen from the rotameter test, the gel mechanical strength formed by P1-Glc+P1-Bob and P1-Man+P1-Bob is almost identical in the neutral state (see figure 42).
2.1.3 Torsion test-test of adhesion stability of hydrogels to pigskin in vitro under external force
The gel was first stained with markowski blue for convenient subsequent observation. And (3) dripping 20 mu L of A, B-component polymer solution on pigskin, waiting for 10 minutes until the solution is completely cured in situ to form hydrogel, applying different stresses such as torsion, folding, stretching and the like on the pigskin, observing whether the gel is stable in adhesion under the condition of being stressed, falling off and cracking, and taking a picture.
The gel coated on the surface of the pigskin can be stably attached to the surface of the pigskin under various deformation states without falling off and cracking. The gel has better adhesion stability (see fig. 43).
2.1.4 Adhesion stability-under water test gel adhesion stability test
The hydrogel was stained with markowski blue to facilitate subsequent observation. After in situ polymerization of the polymer solution droplets on pigskin to form hydrogel, the hydrogel was immersed in PBS buffer solution (ph=7.2), and the solution was changed daily until day 7. And taking out the sample after the soaking is finished, and observing whether the gel can be stably adhered to the surface of the pigskin after the soaking in water for a long time and the adhesion stability under water flow flushing.
The gel can still stably adhere to the tissue surface after being soaked in water for a long time. The gel has better adhesion stability (see fig. 44).
2.1.5 Light transmittance test
The light transmittance test results preliminarily showed that the visible light transmittance of the 0+0 formulation was close to that of carbomer, better than that of the 1+1 formulation, and that the 0+0 flatness was inferior to that of carbomer in practical imaging, and that small wrinkles were easily generated, so that the imaging permeability was slightly inferior Yu Kabo mu gel (see fig. 45), wherein the 0+0 formulation was a formulation of the a-component (Pn-Man, pn-Glc (n=0)) and B-component (Pn-Bob (n=0)), the 1+1 formulation was a formulation of the a-component (Pn-Man, pn-Glc (n=1)) and B-component (Pn-Bob (n=1)), and the 0+1 formulation was a formulation of the a-component (Pn-Man, pn-Glc (n=1)) and B-component (Pn-Bob (n=0)).
2.1.6 In vitro degradation experiments
The gel was shown to have a certain stability in a wet environment and medium-long-term degradability (see fig. 46).
2.1.7 Gel for autologous conjunctival transplantation test
The method comprises the steps of preparing a defect area with the size of 1cm multiplied by 1cm of a bilateral symmetry conjunctiva on a pig eyeball, injecting 12 mu L of hydrogel into the defect area of the conjunctiva in an experimental group, adhering the conjunctiva after waiting for 1min, and naturally covering the conjunctiva in a control group. The displacement areas of the conjunctival flaps were photographed at 0,10, 20, 30, 40min, respectively, and analyzed with Image J. Further, the same conjunctival defect as above was produced, the experimental group was adhered with the conjunctival flap hydrogel, the control group was covered with the conjunctival flap naturally, the conjunctival graft site was rinsed with a continuous water flow after the completion of the graft, and the condition of whether the graft conjunctival flap had fallen off was observed to judge the stability of the adhesion.
The 0+0 and 1+1 gel formulations have good adhesion and can effectively fix conjunctiva and sclera, and the rinsing experiments show that the 0+0 and 1+1 gel formulations have good adhesion and can enable the transplanted conjunctiva tissue to be adhered in situ and not washed away by water flow (see figure 47).
Biomechanical test of 2.1.8 hydrogel-enclosed in vitro porcine eyeball cornea incision
According to the cornea incision closure method, the pig eyes are randomly divided into 4 groups, namely, a suture group, gel0+0 (A component (Pn-Man, pn-Glc (n=0)) and B component (Pn-Bob (n=0))), gel1+1 (A component (Pn-Man, pn-Glc (n=1)) and B component (Pn-Bob (n=1)), a fibrin group, a cornea flap is removed by using a trephine under an operation microscope and placed in an artificial anterior chamber, a microinjection pump is connected to the water inlet end of the artificial anterior chamber, and a differential pressure gauge is connected to the water outlet end, after the artificial anterior chamber is filled to 21mmHg (normal eye pressure value), a linear incision of 2.8mm is made at the near-angle scleral margin by using a cornea main incision knife, a hydrogel of experimental group, a commercial fibrin glue or a suture suturing method is used, the microinjection pump is opened to fill the artificial anterior chamber with liquid, the pumping rate is 10mm/h, the peak reading of the video is recorded, and when the differential pressure reading is changed, whether the liquid leakage occurs or not is observed.
The results show that the 0+0 and 1+1 formulas have less leakage than the suture group and the commercial Fibrin, have better sealing effect and can tolerate the intraocular pressure of more than 200 mmHg. Suitable for closure of corneal wounds (see figure 48).
Example 3 biological experiments on gels
3.1 Biosafety test
SD rats were injected intradermally with 100. Mu.l of P1 Bob+P1Man100. Mu.l prepared in example 1 and sampled for 2 weeks, 1 month, 2 months and 3 months of injection for pathological sections.
The results showed no significant differences between the experimental group and normal skin, and no significant inflammatory reaction was induced, demonstrating good biocompatibility of the gel (see fig. 49).
Cell safety tests showed that the material did not affect cell activity and normal proliferation of cells (see figure 50).
3.2 Autologous conjunctival transplantation of rabbits
The suture, 0+0 (A-component (Pn-Man, pn-Glc (n=0)) and B-component (Pn-Bob (n=0)), 1+1 (A-component (Pn-Man, pn-Glc (n=1)) and B-component (Pn-Bob (n=1)), and commercial materials were compared, respectively.
The results primarily show that the gel group plays a role in transplanting, and tissues at the transplanted positions of the gel group have a restoration trend, so that conjunctival morphology multi-layered squamous epithelium and a small number of goblet cells are seen, and the epithelium regeneration effect is good, equivalent to that of a suture group, and better than that of commercial Fibrin (see figure 51).
Example 4 animal model for cornea injury repair
A single-plane linear main incision of 2.8mm is made on the near-angle scleral edge of the rabbit eye. Nylon suture stitching or gel closure was then performed separately per group.
The monitoring result of the intraocular pressure shows that the intraocular pressure is basically restored to normal intraocular pressure after all groups are adhered to the incision for 3 days, and the treatment means of all groups can effectively seal the incision to avoid anterior chamber leakage.
Anterior ocular segment optical coherence tomography showed that Gel 1+1 (a-component (Pn-Man, pn-Glc (n=1)) and B-component (Pn-Bob (n=1)) groups had more pronounced decrease in internal and external incision thickness at 3-7 days compared to the other groups, which could promote early healing of corneal tissue and edema regression earlier.
The slicing result shows that the Gel1+1 group has the best repairing effect, the tissue structure at the incision is continuous, and the arrangement rule structure of the collagen fibers of the cornea stroma layer is normal.
Overall, gel 1+1 effectively closes the corneal incision, favors early corneal tissue repair and edema regression, and favors correct morphological distribution of the post-operative cornea with best repair effect (see fig. 52).
EXAMPLE 5 bone defect repair animal model
SD rats were placed on the left femoral condyle and a dental drill was used to create 3mm diameter and 3mm deep bone defects. Four groups of rats received the following implants to repair bone defects:
(1) A pathological group, namely performing debridement treatment only on the defect;
(2) Gel1+1 (A-component (Pn-Man, pn-Glc (n=1)) and B-component (Pn-Bob (n=1)) groups, implantation of 40ul of the 1+1 Gel complex of the population at the defect;
(3) Gel2+2 (A-component (Pn-Man, pn-Glc (n=2)) and B-component (Pn-Bob (n=2)) groups, implantation of a total system of 40ul of 2+2 Gel complexes at the defect;
(4) The 2+2RGD group ((A-component (Pn-Man-RGD (n=2)) and B-component (Pn-Bob (n=2))) was implanted with 40ul of the 2+2RGD gel complex of the total system at the defect.
At week 4, rat left femoral condyles were taken and examined using Micro-CT.
CT reconstruction results show (see FIG. 53) that GEL2+2 and GEL2+2RGD treated groups significantly promote bone tissue defect repair relative to the blank and GEL1+1 groups.
The above description is a general description of the application. Variations in form and value may be substituted for the purpose of illustration and not limitation, as the terms are used herein, depending on the circumstances or actual requirements. Various changes and modifications may be made by one skilled in the art, and such equivalents are intended to fall within the scope of the application as defined in the following claims.

Claims (10)

Translated fromChinese
1.一种水凝胶,所述水凝胶由A、B两种聚合物组成,所述A、B两种聚合物的主链由赖氨酸和谷氨酸通过缩聚形成酰胺键构成,n的值为8-100;所述A、B两种聚合物是分别具有任意支化代数的聚合物;所述A、B两种聚合物的结构式如a和b所示:1. A hydrogel, the hydrogel is composed of two polymers A and B, the main chains of the two polymers A and B are composed of amide bonds formed by lysine and glutamic acid through polycondensation, and the value of n is 8-100; the two polymers A and B are polymers with arbitrary branching generations respectively; the structural formulas of the two polymers A and B are shown in a and b:所述A、B两种聚合物主链上的Ra选自(c)或(d),结构式如(c)和(d)所示:Ra on the main chains of the two polymers A and B is selected from (c) or (d), and the structural formulas are shown in (c) and (d):或者 or式中Ra1为A、B两种聚合物主链上的炔基末端连接外源性功能分子;Rb为A、B两种聚合物骨架上侧链氨基末端的支化结构;Rc为和聚合物A的Rb末端连接的单糖或寡糖;Rd为和聚合物B的Rb末端连接的任意苯硼酸结构化合物。In the formula,Ra1 is an exogenous functional molecule connected to the alkynyl terminal on the main chain of polymers A and B; Rb is a branched structure at the amino terminal of the side chain on the backbone of polymers A and B; Rc is a monosaccharide or oligosaccharide connected to the Rb terminal of polymer A; and Rd is any phenylboronic acid structure compound connected to the Rb terminal of polymer B.2.如权利要求1所述水凝胶,其特征在于,所述功能性分子选自肽段、荧光基团、抗菌分子、生长因子、功能性寡糖或多糖中的一种或多种。2. The hydrogel according to claim 1, wherein the functional molecules are selected from one or more of peptides, fluorescent groups, antibacterial molecules, growth factors, functional oligosaccharides or polysaccharides.3.如权利要求1所述水凝胶,其特征在于,所述聚合物A连接的单糖可选自甘露糖、葡萄糖、半乳糖、果糖、木糖、岩藻糖、古洛糖、艾杜糖、来苏糖、甘露糖醛酸、葡萄糖醛酸、半乳糖醛酸、古洛糖醛酸等及其衍生物中的一种或多种,所述聚合物A连接的寡糖可以是任意一种低聚糖的一种或多种。3. The hydrogel according to claim 1, characterized in that the monosaccharide connected to the polymer A can be selected from one or more of mannose, glucose, galactose, fructose, xylose, fucose, gulose, idose, lyxose, mannuronic acid, glucuronic acid, galacturonic acid, guluronic acid and the like and their derivatives, and the oligosaccharide connected to the polymer A can be one or more of any oligosaccharide.4.如权利要求1所述水凝胶,其特征在于,所述聚合物B连接的任意一种苯硼酸结构,包括苯硼酸半酯、羰基苯硼酸半酯中的一种或多种。4. The hydrogel according to claim 1, wherein any one of the phenylboronic acid structures connected to the polymer B comprises one or more of phenylboronic acid half ester and carbonylphenylboronic acid half ester.5.如权利要求1所述的水凝胶,其特征在于,所述所述水凝胶中A、B聚合物的配比为1-2:2-1。5. The hydrogel according to claim 1, characterized in that the ratio of polymer A to polymer B in the hydrogel is 1-2:2-1.6.如权利要求1-5所述的水凝胶在制备皮肤创伤物质中的用途。6. Use of the hydrogel according to claims 1 to 5 in the preparation of skin wound materials.7.如权利要求1-5所述的水凝胶在制备结膜移植或角膜移植中所需缝合剂的用途。7. Use of the hydrogel according to claims 1 to 5 in preparing a suture required for conjunctival transplantation or corneal transplantation.8.一种含权利要求1-5所述的水凝胶的医用制剂。8. A medical preparation comprising the hydrogel according to claims 1-5.9.一种权利要求1-5所述的水凝胶在制备骨修复材料中的应用。9. Use of the hydrogel according to claims 1 to 5 in preparing bone repair materials.10.一种如权利要求1-5所述的水凝胶的制备方法:10. A method for preparing the hydrogel according to claims 1-5:S1.中间产物1的制备:S1. Preparation of intermediate 1:原料Boc-Lys(Boc)-OH、H-Glu(OMe)-OMe·HCl在试剂EDC、HOBT、DIPEA作用下发生缩合反应,得到中间产物1.The raw materials Boc-Lys(Boc)-OH and H-Glu(OMe)-OMe·HCl underwent condensation reaction under the action of reagents EDC, HOBT and DIPEA to obtain the intermediate product 1.S2.中间产物2的制备:S2. Preparation of intermediate product 2:中间产物1在试剂氯化氢乙酸乙酯溶液作用下发生脱保护反应,得到中间产物2.Intermediate product 1 undergoes a deprotection reaction under the action of a reagent, hydrogen chloride ethyl acetate solution, to obtain intermediate product 2.S3.中间产物3的制备:S3. Preparation of intermediate product 3:中间产物2和原料Boc-Lys(Boc)-OH在试剂EDC、HOBT、DIPEA作用下发生缩合反应,得到中间产物3.Intermediate product 2 and raw material Boc-Lys(Boc)-OH undergo condensation reaction under the action of reagents EDC, HOBT, and DIPEA to obtain intermediate product 3.S4.中间产物4、5的制备:S4. Preparation of intermediate products 4 and 5:中间产物1或3在试剂氢氧化锂作用下发生脱保护反应,分别得到中间产物4或5.Intermediate product 1 or 3 undergoes a deprotection reaction under the action of lithium hydroxide reagent to obtain intermediate product 4 or 5, respectively.S5.中间产物6、7、8的制备:S5. Preparation of intermediate products 6, 7, and 8:原料Boc-Glu-OH或中间产物4或5和原料五氟苯酚在试剂EDC作用下发生缩合反应,分别得到中间产物6、7、8.The raw material Boc-Glu-OH or the intermediate product 4 or 5 and the raw material pentafluorophenol undergo condensation reaction under the action of the reagent EDC to obtain the intermediate products 6, 7, and 8, respectively.S6.中间产物9的制备:S6. Preparation of intermediate product 9:原料Boc-Lys(Boc)-OH和炔丙基胺在试剂EDC、HOBT、DIPEA作用下发生缩合反应,得到中间产物9.The raw material Boc-Lys(Boc)-OH and propargylamine reacted with the reagents EDC, HOBT and DIPEA to obtain the intermediate product 9.S7.中间产物10(Mb)的制备:S7. Preparation of intermediate product 10 (Mb):中间产物9在试剂氯化氢乙酸乙酯溶液作用下发生脱保护反应,得到中间产物10(Mb).Intermediate product 9 was deprotected by hydrogen chloride ethyl acetate solution to obtain intermediate product 10 (Mb).S8.中间产物11(Mc)的制备:S8. Preparation of intermediate product 11 (Mc):原料Boc-胺氧基乙酸、五氟苯酚在试剂EDC作用下发生缩合反应,得到中间产物11(Mc).The raw materials Boc-aminoacetic acid and pentafluorophenol underwent condensation reaction under the action of the reagent EDC to obtain the intermediate product 11 (Mc).S9.中间产物12、13、14的制备:S9. Preparation of intermediates 12, 13, 14:中间产物6或7或8和中间产物10(Mb)在试剂DIPEA作用下发生聚合反应,得到中间产物12、13、14.Intermediate product 6 or 7 or 8 and intermediate product 10 (Mb) undergo polymerization reaction under the action of reagent DIPEA to obtain intermediate products 12, 13, and 14.S10.中间产物15、16、17的制备:S10. Preparation of intermediates 15, 16, and 17:中间产物12或13或14在试剂三氟乙酸作用下发生脱保护反应,分别得到中间产物15、16、17.Intermediate product 12, 13 or 14 undergoes deprotection reaction under the action of trifluoroacetic acid to obtain intermediate products 15, 16 and 17, respectively.S11.B组分(产物18、19、20)的制备:Preparation of S11.B component (products 18, 19, 20):中间产物15或16或17和原料Bob在试剂硼氢化钠作用下发生反应,分别得到产物B组分(产物18、19、20).The intermediate product 15 or 16 or 17 reacts with the raw material Bob under the action of the reagent sodium borohydride to obtain the product B component (product 18, 19, 20).S12.中间产物21、22、23的制备:S12. Preparation of intermediates 21, 22, and 23:中间产物15或16或17和中间产物11(Mc)在试剂DIPEA作用下发生缩合反应,并进一步在试剂三氟乙酸作用下发生脱保护反应,分别得到中间产物21、22、23.Intermediate 15 or 16 or 17 and intermediate 11 (Mc) undergo condensation reaction under the action of reagent DIPEA, and further undergo deprotection reaction under the action of reagent trifluoroacetic acid to obtain intermediates 21, 22, and 23, respectively.S13.A组分(产物24、25、26)的制备:Preparation of S13.A component (products 24, 25, 26):中间产物21或22或23和原料单糖或寡糖在试剂苯胺作用下发生缩合反应,分别得到产物A组分(产物24、25、26);The intermediate product 21 or 22 or 23 and the raw material monosaccharide or oligosaccharide undergo condensation reaction under the action of the reagent aniline to obtain product A component (product 24, 25, 26) respectively;S14.水凝胶的合成S14. Synthesis of HydrogelA组分或B组分固含量在12wt%~20wt%配制。The solid content of component A or component B is prepared at 12wt% to 20wt%.
CN202310704935.7A2023-06-142023-06-14Preparation of hydrogels and uses thereofPendingCN119144151A (en)

Priority Applications (2)

Application NumberPriority DateFiling DateTitle
CN202310704935.7ACN119144151A (en)2023-06-142023-06-14Preparation of hydrogels and uses thereof
PCT/CN2024/099071WO2024255806A1 (en)2023-06-142024-06-13Preparation and use of hydrogel

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN202310704935.7ACN119144151A (en)2023-06-142023-06-14Preparation of hydrogels and uses thereof

Publications (1)

Publication NumberPublication Date
CN119144151Atrue CN119144151A (en)2024-12-17

Family

ID=93813188

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN202310704935.7APendingCN119144151A (en)2023-06-142023-06-14Preparation of hydrogels and uses thereof

Country Status (2)

CountryLink
CN (1)CN119144151A (en)
WO (1)WO2024255806A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP2508544A1 (en)*2011-04-042012-10-10Argon Pharma S.L.Degradable polyacetal polymers
KR101444877B1 (en)*2011-12-302014-10-01주식회사 삼양바이오팜In situ crosslinking hydrogel comprising γ-polyglutamic acid and method for producing the same
CN102964593B (en)*2012-12-172015-02-18中国科学院长春应用化学研究所Block polymer, preparation method thereof and electrically active hydrogel
CN103656729B (en)*2013-12-112015-06-17南京工业大学Hydrogel based on gamma-polyglutamic acid and polylysine cross-linked polymer and preparation method thereof
CN109912791B (en)*2019-03-272021-11-16南京邦鼎生物科技有限公司Carboxylated PEG derivative, hydrogel based on PEG derivative, and preparation method and application of carboxylated PEG derivative and hydrogel

Also Published As

Publication numberPublication date
WO2024255806A1 (en)2024-12-19

Similar Documents

PublicationPublication DateTitle
Zhao et al.Natural polymer-derived photocurable bioadhesive hydrogels for sutureless keratoplasty
Shen et al.Dual-crosslinked regenerative hydrogel for sutureless long-term repair of corneal defect
JP5661722B2 (en) Ophthalmic device and manufacturing method thereof
CN113336973B (en) A kind of repair-promoting double-network hydrogel and preparation method and application thereof
CA2577025C (en)Vision enhancing ophthalmic devices and related methods and compositions
Qian et al.Dopamine‐based high‐transparent hydrogel as bioadhesive for sutureless ocular tissue repair
US20040131582A1 (en)Novel dendritic polymers and their biomedical uses
WO2023020256A1 (en)Biological polysaccharide hydrogel, preparation method therefor and application thereof
Liu et al.Sutureless transplantation using a semi-interpenetrating polymer network bioadhesive for ocular surface reconstruction
CA3111444A1 (en)Light activated adhesive scaffold
CN113926001B (en)Bionic cornea and preparation method thereof
JP4006039B2 (en) Photocrosslinked hyaluronic acid contact lens
US20230263943A1 (en)Hydrogels for in situ-forming tissue constructs
CN110384822B (en)Adhesive sealing glue for eyes and preparation method thereof
WO2023035720A1 (en)Method for preparing pegylated collagen-like protein and use thereof
CN114767920A (en) A kind of polyethylene glycol based adhesive and its preparation method and application
CN108404207A (en)The preparation method of temperature sensitive aquagel cell factor compound rest
CN119144151A (en)Preparation of hydrogels and uses thereof
CN119101249B (en)Retina filling hydrogel and preparation method and application thereof
TW201223566A (en)Thremosensitivity hydrogel for tissue engineering and use thereof
Zhang et al.A dual-layer convex patch based on collagen-gelatin/alginate for corneal stroma defects repair and irregular penetrating injuries healing
CN118512387A (en)Sodium hyaluronate micro-needle patch for eyes and preparation method and application thereof
CN118662685A (en)Hydrogel adhesive and application thereof
CN118873729A (en) A bioadhesive, a bioadhesive pre-solution and its application
HK1125395B (en)Interpenetrating networks, and related methods and compositions

Legal Events

DateCodeTitleDescription
PB01Publication
PB01Publication

[8]ページ先頭

©2009-2025 Movatter.jp